Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bicycle Therapeutics plc - American Depositary Shares (NQ: BCYC )

11.25 -0.41 (-3.52%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 231,377
Open 11.72
Bid (Size) 11.23 (1)
Ask (Size) 11.24 (2)
Prev. Close 11.66
Today's Range 11.22 - 11.81
52wk Range 11.14 - 28.67
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bicycle Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Bicycle Therapeutics plc
Via Business Wire

Performance

YTD
-21.66%
-21.66%
1 Month
-13.33%
-13.33%
3 Month
-43.61%
-43.61%
6 Month
-50.13%
-50.13%
1 Year
-55.99%
-55.99%

More News

Read More
Forecasting The Future: 11 Analyst Projections For Bicycle Therapeutics
Via Benzinga
Bicycle Therapeutics Announces Updated Topline Zelenectide Pevedotin Data and Highlights 2025 Strategic Priorities and Milestones
From Bicycle Therapeutics plc
Via Business Wire
Breaking Down Bicycle Therapeutics: 8 Analysts Share Their Views
Via Benzinga
Navigating 11 Analyst Ratings For Bicycle Therapeutics
Via Benzinga
Bicycle Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Bicycle Therapeutics plc
Via Business Wire
Amazon To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients
Via Benzinga
Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Expands Clinical Advisory Board with Three Distinguished Global Oncology Experts
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program Update
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces First Human Imaging Data from European Association of Nuclear Medicine 2024 Congress and Outlines Strategy for Leadership in Next-Generation Radiopharmaceuticals
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics to Present Radiopharmaceuticals Data at European Association of Nuclear Medicine 2024 Congress
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Bicycle Therapeutics plc
Via Business Wire
BCYC: A Promising Play In The Biotech Sector
Via Talk Markets
Topics ETFs
Bicycle Therapeutics Presents Updated Clinical Results Across Oncology Pipeline at ESMO Congress 2024
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics' Lead Cancer Candidate's Has High-Opportunity, Analyst Initiates With Bullish Tone
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.